Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs PayPal Holdings, Inc. (PYPL) Price & Performance

Kymera Therapeutics Inc. Common StockTrade
PayPal Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Kymera Therapeutics Inc. Common Stock vs PayPal Holdings, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while PayPal Holdings, Inc. trades at $56.17 (market cap $48.05B). The key difference: PayPal Holdings, Inc. is far larger — about 5.4× Kymera Therapeutics Inc. Common Stock's market cap, and PayPal Holdings, Inc. pays a 1% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and PayPal Holdings, Inc. for 106 Days on average.

KYMRPYPL
Market Cap
$8.87B$48.05B
Volume
779,1077,905,570
Sector
HealthFinancials
52-Week High
$127.31$73.01
52-Week Low
$55.80$39.08
Typical Hold Time
0 Days106 Days
Enterprise Value
$8.26B$50.20B
Dividend Yield
—1%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kymera Therapeutics Inc. Common Stock

No Aura AI signal available yet.

PayPal Holdings, Inc.

PayPal trades at $56.10, up 0.09% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $31.8B in 2024 to $33.2B in 2025 and net income of $5.23B. Valuation metrics appear attractive with P/E of 10.62 and EV/EBITDA of 6.89. Recent Q2 2026 earnings beat expectations at $1.38 EPS versus $1.28 expected. The company maintains robust cash flow with $1.53B net cash flow in 2025 and recently announced a Meta partnership for AI-powered checkout.

PayPal presents a compelling value opportunity with reasonable valuation and solid financials, though faces competitive pressures in digital payments. Analyst consensus is mixed with 35.7% buy ratings but a $56.41 price target suggesting limited upside. Key risks include checkout competition and slowing growth, balanced by new CEO's turnaround focus on Venmo, BNPL, and cost efficiency initiatives.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KYMR
100% Buy0% Sell
Avg holding period · 0 Days
PYPL
41% Buy59% Sell
Avg holding period · 106 Days

Top news

Latest headlines on both assets

About Kymera Therapeutics Inc. Common Stock

Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.

Read more on KYMR →

About PayPal Holdings, Inc.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.

Read more on PYPL →